Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA’s Opioid Crisis Response: More Pressure For Treatment Drugs

Executive Summary

Sharp increases in deaths from illicit drugs (heroin and synthetic opioids) could change FDA's priorities; rather than working with drug sponsors on more tamper-deterrent formulations of pain therapies, the agency may need to devote more attention to overdose treatments like naloxone.

Advertisement

Related Content

Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA
Higher Naloxone Doses Narrowly Favored By FDA Panel

Topics

Advertisement
UsernamePublicRestriction

Register

PS119344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel